$CNSY Cashflow Statement | Understand Stock

$CNSY

$1.66 +$0.09 (5.73%) Close

$CNSY Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization of deferred financing costs and debt discount
In process research and development acquired
Common stock issued for research and development
Accretion of discount on short-term investments
Noncash financing expenses
Change in fair value of warrants
Change in fair value of derivative instruments
Stock compensation expense
Inventory write off
Non-cash lease expense
Reduction in the carrying amount of operating lease right-of-use assets
Gain on sale of assets
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable
Other current assets
Grant receivable
Other assets
Accounts payable and accrued expenses
Other liabilities
Change in operating lease liabilities
Other long-term liabilities
Deferred grant liability

Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment and intangible assets
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchases of intangible assets
Purchases of short-term investments
Proceeds from redemption of short-term investments
Proceeds from sales of short-term investments
In process research and development acquired
Net cash used in investing activities

Cash flows from financing activities:
Principal payments of term loan obligation
Payment of finance lease liability
Proceeds from exercise of warrants
Proceeds from credit facility
Repayment of credit facility
Payment of financing costs
Proceeds from issuance of notes payable and warrants
Repayment of notes payable
Proceeds from sale of common stock, pre-funded warrants, and warrants
Proceeds from sale of common stock under Lincoln Park Purchase Agreement
Payment to investors pursuant to Letter Agreement
Proceeds from sale of common stock, net of offering costs of $0.2 million
Offering costs for sale of common stock
Common stock issued in payment for in process research and development
Reclassification of warrants liability to equity
Purchase of treasury stock
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Cash paid during period for:
Interest
Supplemental schedule of non-cash investing and financing activities:
Unpaid offering cost
Unpaid liability to investors pursuant to Letter Agreement
Exchange of warrants for notes payable
Redemption of notes by issuance of common stock, pre-funded warrants and warrants
Common stock issued in payment for in process research and development
Right-of-use assets acquired by assuming operating lease liabilities

Comments